|1.||Morris, John C: 38 articles (11/2015 - 09/2003)|
|2.||Meguro, Kenichi: 23 articles (05/2015 - 03/2003)|
|3.||Alzheimer's Disease Neuroimaging Initiative: 22 articles (04/2015 - 11/2008)|
|4.||Lam, Linda C W: 16 articles (01/2013 - 01/2005)|
|5.||Roe, Catherine M: 15 articles (11/2015 - 10/2003)|
|6.||Engedal, Knut: 14 articles (01/2014 - 08/2006)|
|7.||Morris, J C: 14 articles (03/2012 - 01/2000)|
|8.||Ganguli, Mary: 13 articles (11/2015 - 11/2002)|
|9.||Yamaguchi, Satoshi: 13 articles (07/2013 - 03/2003)|
|10.||Chiu, Helen F K: 13 articles (01/2013 - 01/2005)|
06/01/2007 - "Total NT length in all areas studied increased in mildly demented cases but showed a marked decrease in Clinical Dementia Rating (CDR) scale 3 cases. "
01/01/2011 - "Our results have showed 60% of recruited AD patients improved in cognition, measured by Mini-Mental Status Examination (MMSE), and 57.1% in global status, by Clinical Dementia Rating Scale (CDR) sum of boxes (CDR-SB). "
04/18/2008 - "The detection sensitivity of the method was 40pg/ml. Rates of subjects positive for monomeric Abeta according to their clinical dementia rating (CDR) were 11.1% for CDR 0, 62.5% for CDR 0.5, 83.3% for CDR 1, 54.5% for CDR 2 and 0% for CDR 3. A single Abeta band relative to the CDR score reflects an alteration in the production, solubility and clearance of Abeta in the brain. "
07/01/2007 - "The aim of this study was to determine the diagnostic value and agreement analyses between Clinical Dementia Rating (CDR) and dementia diagnostic criteria (gold standard), Blessed Dementia Rating scale (BDRS), and Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised (DSM III-R) criteria for severity. "
08/01/2010 - "Staging was according to the Clinical Dementia Rating Scale (CDR) on the basis of clinical data but independent of computerized cognitive testing results, thus serving as the gold standard for evaluating the discriminant validity of the computerized measures. "
04/28/2005 - "The deoxycytidine analog 5-aza-2'-deoxycitidine (5-aza-dC) is a potent chemotherapeutic agent effective against selective types of cancer. "
04/01/2015 - "In this study we used the Swedish National Inpatient Register (IPR) and Causes of Death Register (CDR) to further study the incidence comparing with the Cancer Register data for the time period 1998-2013 using joinpoint regression analysis. "
04/01/2015 - "In this study, six expert breast imagers used a method based on the Angoff approach to update criteria for acceptable mammography performance on the basis of two sets of combined performance measures: set 1, sensitivity and specificity for facilities with complete capture of false-negative cancers; and set 2, cancer detection rate (CDR), recall rate, and positive predictive value of a recall (PPV1) for facilities that cannot capture false-negative cancers but have reliable cancer follow-up information for positive mammography results. "
10/01/2015 - "At blinded double reading, arbitration would have decreased recall rate (3.4 to 2.2%, p < 0.001) and programme sensitivity (83.2 to 76.0%, p = 0.013), would not have influenced the cancer detection rate (CDR; 7.5 to 6.8 per 1,000 screens, p = 0.258) and would have increased the positive predictive value of recall (PPV; 22.3 to 31.2%, p < 0.001). "
09/01/2015 - "Although patients' tolerance is an important issue in TRUS-Bx, cancer detection rate (CDR) must not be ignored. "
01/01/1998 - "These results indicate that a single CDR can be effective against RSV infection."
07/01/2014 - "As community viral load (CVL) measurements are associated with the incidence of new HIV-1 infections in a population, we hypothesized that similarly measured community drug resistance (CDR) could predict the prevalence of transmitted drug resistance (TDR). "
05/01/2014 - "Their unmutated ancestor emerged between weeks 30-38 post-infection with a 35-residue CDR H3, and neutralized the virus that superinfected this individual 15 weeks after initial infection. "
05/01/2014 - "CDR and HDR are valid sources for identifying infection and may supplement each other for increased completeness of infection-related death in epidemiologic research."
05/01/2014 - "The positive predictive value of an infection diagnosis was 96.0% (95% CI, 92.0%-98.3%) in the CDR and 95.3% (CI, 90.9%-97.9%) in the HDR. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
12/01/2007 - "Gemcitabine (2'-deoxy-2'-difluoro-deoxycytidine: Gemzar) appears to be the only clinically effective drug for pancreatic cancer, but it has little impact on outcome. "
09/01/2000 - "Gemcitabine (Gem) is a deoxycytidine analog that is effective against pancreatic cancer and other malignancies following conversion to the 5'-O-mono-, di- and tri-phosphate forms. "
05/01/2015 - "The epigenetic agents suberoylanilide hydroxamic acid and 5‑AZA‑2' deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo."
07/16/2007 - "Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. "
11/15/2003 - "Although gemcitabine, a deoxycytidine analogue, recently demonstrated improvements in the response rate for pancreatic cancer, the median survival for patients is limited to 4-6 months. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/1999 - "A proto-oncogene, MTG8 (ETO/CDR), is disrupted in the t(8;21) translocation associated with acute myeloid leukemia, and the gene product, MTG8, is a phosphoprotein capable of cell transformation in concert with v-H-ras. "
02/01/1998 - "In the t(8;21) translocation associated with acute myeloid leukemia (AML), the AML1(CBFA2/PEBP2alphaB) gene is juxtaposed to the MTG8(ETO/CDR) gene. "
04/30/2002 - "Mutant fish harboring deletions affecting the 5q CDR syntenic region may provide useful animal models for investigating the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia."
05/01/1998 - "The t(8;21) translocation associated with acute myeloid leukemia (AML) disrupts two genes, the AML1 gene also known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO. "
01/01/2011 - "TaraC shares similar structure with another anticancer deoxycytidine analog, β-D-arabinofuranosylcytosine (araC, cytarabine), which has been used in clinics for the treatment of acute myelogenous leukemia but has a very limited efficacy against solid tumors. "
|2.||Complementarity Determining Regions (Complementarity Determining Region)
|9.||fibrin fragment D (D-dimer)
|1.||Activities of Daily Living (ADL)
|2.||Drug Therapy (Chemotherapy)
|4.||Home Nursing (Nursing, Home)
|5.||Institutionalization (Institutionalized Persons)